131I治疗Graves甲状腺功能亢进症中碳酸锂的应用

131I治疗Graves甲状腺功能亢进症(甲亢)的有效性取决于其在甲状腺内的滞留时间,且受治疗前抗甲状腺药物使用、肿大甲状腺容积和甲状腺24 h摄碘率等因素的影响.锂具有阻止有机碘和甲状腺激素自甲状腺内释出的作用而不影响甲状腺对131I的摄取,因此,131I治疗Graves甲亢前后辅以短程、小剂量碳酸锂,具有提高甲状腺...

Application of lithium carbonate on radioiodine treatment of Graves' hyperthyroidism

Effectiveness of radioiodine for Graves' hyperthyroidism depends on retention time of 131I in the thyroid, and may be effected by several factors, including previous treatment with antithyroid drugs,goiter volume, 24 h thyroidal radioactive iodine uptake and so on. A short course of therapy with low dose of lithium carbonate increased retention of 131I in the thyroid and prolong the intrathyroidal effective half-life of 131I before and after 131I therapy in patients with Graves'disease, because of the actions that lithium blocks the release of organic iodine and thyroid hormone from the thyroid gland without affecting thyroidal radioactive iodine uptake. Therefore, using lithium as adjunct to radioiodine therapy increases the radiation dose delivered to the thyroid, to result in reduced the activity required and whole-body radiation dose in patients with very short effective half-life, and so improve the cure rate of hyperthyroidism. A short course of lithium carbonate therapy can be considered a useful adjunct to 131I therapy for obtaining a more rapid control of thyrotoxicosis and avoiding its transient exacerbation because of methimazole withdrawal prior to 131I administration or in patients who cannot tolerate or do not respond to antithyroid drugs, and for helping to prevent the radioiodineassociated increase in serum free thyroid hormone concentrations. In addition, lithium carbonate enhances the effectiveness of 131I therapy, in terms of prompter control of hyperthyroidism in patients with small or large goiters. At the same time, lithium also may increases the rate of permanent control of hyperthyroidism in patients with large goiters. In summary, in the short-term lithium plays an important role as an adjunct to 131I,since it helps to prevent the 131I-associated increase in serum free thyroid hormone concentrations and allows a more prompt control of thyrotoxicosis. This is of particular importance in highrisk patients, such as the elderly,those with severe hyperthyroidism, underlying cardiovascular disorders, or other severe nonthyroidal illness for whom even a transient exacerbation of the thyrotoxicosis may be dangerous. Treatment with a relatively low dose of lithium before and after 131I therapy offers a safe and effective alternative means of controlling thyrotoxicosis in patients with Graves disease.